Further, pre-clinical studies are needed to clarify whether global LDLR inhibition is more beneficial—attenuating pancreatic cancer without significant side effects—or targeting LDLR specifically in pancreatic cancer is necessary. The gene discussed is LDLR; the disease is pancreatic neoplasm.